iShares Core MSCI Emerging Markets ETF vs Twist Bioscience Corp — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 16.1× Twist Bioscience Corp's market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (13,446,151 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Twist Bioscience Corp for 27 Days on average.
| IEMG | TWST | |
|---|---|---|
Market Cap | $162.00B | $10.08B |
Volume | 13,446,151 | 4,229,037 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $205.00 |
52-Week Low | $64.22 | $25.45 |
Typical Hold Time | 57 Days | 27 Days |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
IEMG is trading at $80.5, down 1.88% over the past 24 hours amid a bearish technical signal. The ETF's technical indicators show selling pressure with moving averages signaling bearish momentum, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers, with the fund delivering 35% returns over the past year according to Fool - Investing News on 2026-07-06, though it faces higher volatility than broader international alternatives.
The outlook for IEMG remains mixed with technical weakness offset by strong recent performance in emerging markets. Key risks include concentration in technology sectors (39% weighting) and higher volatility compared to developed market ETFs. Analyst comparisons favor IEMG for emerging market exposure but note cost disadvantages versus competitors like SCHE with its 0.03% expense ratio versus IEMG's 0.09%.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →